MedTrace Logo

A Decentralized Clinical Study Evaluating the Effectiveness of Two Different Doses of MyCondro™ on Physical Mobility and Joint Health

NCT07493239 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2026-07-22

No results posted yet for this study

Summary

This study evaluates the effect of two different doses of a consumer-grade product, MyCondro™, on individuals experiencing mobility issues related to knee osteoarthritis. The primary goal is to measure improvements in overall joint health and mobility by tracking changes in participants' total WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index) scores from the beginning to the end of the trial. Additionally, the study aims to assess secondary outcomes, including the product's impact on pain, stiffness, knee function, patient-reported improvement, inflammatory blood markers (CRP), and daily physical activity.

Conditions

  • Joint Health

Interventions

DIETARY_SUPPLEMENT

MyCondro 300mg

This is a non-animal Chondroitin sulfate formulation.

DIETARY_SUPPLEMENT

MyCondro 600mg

This is a non-animal Chondroitin sulfate formulation.

Sponsors & Collaborators

  • Lesaffre International

    lead INDUSTRY

  • People Science, Inc.

    collaborator INDUSTRY

Principal Investigators

  • Noah Craft, MD, PhD · People Science, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-04
Primary Completion
2026-10-05
Completion
2026-11-02

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07493239 on ClinicalTrials.gov